Synopsis: Unihealth Hospitals Limited has grabbed intense stock market attention on Wednesday, June 17, 2026, after hitting the 5.00% upper circuit at Rs. 548. The small-cap healthcare powerhouse announced a strategic share-swap deal to consolidate its ownership in its highly profitable Ugandan subsidiary, Victoria Hospital Limited.
In a major corporate filing submitted to the National Stock Exchange (NSE), Mumbai-headquartered Unihealth Hospitals Limited (formerly known as Unihealth Consultancy Limited) announced that its board has approved a strategic share-swap arrangement. The transaction is meticulously designed to increase the company’s equity stake from its current 50.00% holding to an outright majority position by acquiring the remaining 50.00% from its East African joint-venture partners. The final share-exchange ratio will be determined via independent valuation reports, helping the company preserve cash liquidity while aggressively accumulating high-growth assets abroad.
The strategic rationale behind the acquisition is rooted in the explosive financial performance of Victoria Hospital Limited, which operates under the premier ‘UMC Victoria Hospital’ brand in Kampala, Uganda. During FY 2025–26, the African hospital asset emerged as a major cash cow. Its annual revenue surged by 33.12% to Rs. 114.47 crore, up from Rs. 85.99 crore in the previous fiscal cycle.
More impressively, its Profit After Tax (PAT) witnessed a stellar 69.04% jump to Rs. 43.63 crore against Rs. 25.81 crore in the prior year. By shifting from a joint venture to complete consolidation, Unihealth will significantly boost its bottom line and offer immediate earnings visibility to domestic investors.
Dr. Akshay Parmar, Founder and Managing Director of Unihealth Hospitals Limited, emphasized that the move aligns with their broader mission of capturing high-growth medical opportunities across emerging African nations. Beyond its core tertiary care center in Kampala celebrated for its oncology, spine surgery, and cardiology capabilities the entity recently commissioned a new 30-bed hospital facility in Entebbe.
The group plans to build an expansive, country-wide web of secondary clinics over the next 12 months. This comes alongside localized expansions into Nashik, India, where its brand-new UMC Hospital facility just secured official registration and is slated to welcome patients within the coming weeks.
Unihealth Hospitals stock witnessed an aggressive wave of buying on the NSE SME Emerge platform. The shares locked into their daily upper circuit limit, jumping +4.94% to trade at an all-time high of Rs. 548.00. The company has turned into a massive multi-bagger for early public investors, charting a sensational 1-year return profile of 213% from its 52-week low of Rs. 134.00.
The medical operator currently commands a total market capitalization of Rs. 871 crore. Financially, the company shows outstanding capital efficiency metrics, recording a Return on Capital Employed (ROCE) of 27.40% and a Return on Equity (ROE) of 21.40%. The stock is currently trading at a price-to-earnings (P/E) multiple of 33.7, presenting a visible valuation discount compared to the broader domestic hospital sector median industry P/E of 45.4. This attractive headroom has fueled a strong institutional appetite, pushing promoter holdings to a stable 69.50%.
Company Overview
Incorporated in 2010, Unihealth Hospitals Limited is a globally diversified healthcare service provider with operational roots in Mumbai and a powerful delivery footprint across East Africa. Listed on the NSE Emerge platform in September 2023, the organization spans a versatile spectrum of medical businesses. This includes direct tertiary hospital operations, healthcare project management consultancy, medical value travel facilitation, and the international distribution of essential Indian pharmaceutical and medical equipment. For the full fiscal year FY26, the company recorded a consolidated annual total income of Rs. 137.01 crore and an EBITDA of Rs. 58.82 crore.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
